Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Profile of RFA with Nivolumab in Liver Tumors
NCT04707547Phase 4Completed
- Sponsor
- Taipei Medical University WanFang Hospital
- Start
- Oct 2019
- Primary completion
- Jul 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of nivolumab in liver cancer, sponsored by Taipei Medical University WanFang Hospital. Started Oct 2019; status: completed.
02
Drugs
03
Conditions
liver cancer
Beyond the preview
Go deeper on NCT04707547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04707547.